1. Home
  2. USA vs BEAM Comparison

USA vs BEAM Comparison

Compare USA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USA

Liberty All-Star Equity Fund

HOLD

Current Price

$6.17

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.39

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USA
BEAM
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
USA
BEAM
Price
$6.17
$27.39
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$48.09
AVG Volume (30 Days)
880.5K
1.9M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.62
$13.53
52 Week High
$7.09
$35.25

Technical Indicators

Market Signals
Indicator
USA
BEAM
Relative Strength Index (RSI) 52.22 59.68
Support Level $5.80 $25.86
Resistance Level $6.20 $28.28
Average True Range (ATR) 0.06 1.63
MACD 0.02 0.37
Stochastic Oscillator 83.81 74.98

Price Performance

Historical Comparison
USA
BEAM

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: